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Background: To estimate the short- and long-term financial impact of early referral for implantable loop recorder
diagnostic (ILR) versus conventional diagnostic pathway (CDP) in the management of unexplained syncope (US) in
the Portuguese National Health Service (PNHS).
Methods: A Markov model was developed to estimate the expected number of hospital admissions due to US and
its respective financial impact in patients implanted with ILR versus CDP. The average cost of a syncope episode
admission was estimated based on Portuguese cost data and landmark papers. The financial impact of ILR adoption
was estimated for a total of 197 patients with US, based on the number of syncope admissions per year in the
PNHS. Sensitivity analysis was performed to take into account the effect of uncertainty in the input parameters
(hazard ratio of death; number of syncope events per year; probabilities and unit costs of each diagnostic test;
probability of trauma and yield of diagnosis) over three-year and lifetime horizons.
Results: The average cost of a syncope event was estimated to be between 1,760€ and 2,800€. Over a lifetime
horizon, the total discounted costs of hospital admissions and syncope diagnosis for the entire cohort were 23%
lower amongst patients in the ILR group compared with the CDP group (1,204,621€ for ILR, versus 1,571,332€
for CDP).
Conclusion: The utilization of ILR leads to an earlier diagnosis and lower number of syncope hospital admissions
and investigations, thus allowing significant cost offsets in the Portuguese setting. The result is robust to changes in
the input parameter values, and cost savings become more pronounced over time.
Keywords: Syncope, Implantable loop recorder, Emergency department, Budget impact analysisBackground
Syncope represents a major health challenge for the
medical team diagnosing its etiology, which can range
from benign neurocardiogenic syncope to potentially
fatal arrhythmias. The frequency of syncope episodes at
the emergency department is reported in recent studies
to range from 0.9% to 1.7% of all attendances [1-8]. Due* Correspondence: rui_providencia@yahoo.com
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distribution, and reproduction in any mediumto the potentially life-threatening etiology of syncope, pa-
tients often undergo a long and costly clinical pathway,
which sometimes comprises extensive and repeated inves-
tigations. For this reason, syncope represents a clinical
challenge and a financial burden to health care systems
[9-11].
Evidence regarding the clinical and economic benefit of
the implantable loop recorder (ILR) for the etiologic study
of recurrent syncope has grown in recent years [12,13] and
the use of such devices is currently supported by the 2009
European Society of Cardiology Syncope Guidelines [14].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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cope patients have focused on a 12-month period of time
as opposed to a cohort-level analysis comparing ILR with
non-ILR strategies over the lifetime of the patients [4,15,16.
Moreover, none of these analyses has been performed
within the Portuguese healthcare setting.
We aimed to estimate the financial impact of adopting
Implantable Loop Recorder Diagnostic for the diagnosis of
unexplained syncope versus a conventional diagnostic




A discrete-time Markov chain was developed to estimate
the expected number of hospital admissions due to un-
explained syncope, and respective financial impact in pa-
tients implanted with ILR versus patients following the
conventional diagnostic pathway, over 3-year and lifetime
(30 years) time horizons. The 3-year period was chosen to
reflect the current battery life of leading ILRs [17]. The
model considered three health states (undiagnosed syn-
cope, diagnosis and death), and two groups with different
state transition probabilities – ILR and CDP (Figure 1).
Each year, patients with undiagnosed syncope faced the
probability of death, of a recurrent syncope event and in
case of a syncope event, the probability of being diag-
nosed. Once a diagnosis was achieved (assuming that the
patient is successfully treated) or death occurred, the pa-
tient exited the model and no further costs or syncope
events were modelled. The state transition probabilities
were taken from landmark papers as described below.
The probability of death in both patient groups was
based on the Portuguese Population age–specific mortality
rate [18]. Following Soteriades et al. [11], this rate was ad-
justed by a factor of 1.32 to take into consideration theFigure 1 Schematics of the model proposed. The model
considers two groups, Implantable Loop Recorder (ILR) and
Conventional Diagnostic Pathway (CDP) groups, with different
state-transition probabilities (μ,; σ, syncope; and δ, diagnosis).
(US = undiagnosed syncope).adjusted hazard ratio for the risk of death from any cause
in patients with unexplained syncope. We applied a rate of
0.6 syncopes per year among undiagnosed patients in both
arms (the value was adjusted to the 3-month cycle length
used), based on follow-up data from Farwell [19]. This is
consistent with data from Brignole, who reported a mean
of 0.83 syncopes per year during follow-up [20]. This is a
conservative approach, since a higher syncope recurrence
rate would favour ILR due to its improved diagnostic
power.
The probability of diagnosis should a recurrent syncope
event occur was modelled on a probability-per-event basis –
we used 62.8% for the ILR arm, based on data on the rate of
successful ECG capture (either automatic or manual from
the device after a syncope event) in the EaSyAS study re-
ported by Farwell [19] (27 patients out of 43 were success-
fully diagnosed). This diagnosis rate was applied only in the
first three years of the model, to reflect the battery lifetime
of the ILR. In the CDP group, a diagnosis rate per syncope
of 12.5% was used, also based on data from Farwell [19] (4
out of 32 patients were diagnosed in the control arm). This
diagnosis rate was also applied beyond 3 years in the ILR
group, due to exhaustion of the ILR battery – the assump-
tion therefore is that the ILR will not be replaced if a diag-
nosis has not been achieved within three years of
implantation. We used the EaSyAS study as the source for
these parameters to avoid introducing bias through use of
data from different studies, even though a more recent
study included the latest version of the ILR, which has sig-
nificant algorithm improvements and better performance
(e.g. older-generation devices sometimes failed to auto-
activate) [21]. Sensitivity analyses were undertaken to ex-
plore the impact of different data sources for the incidence
of recurrent syncope and the probability of diagnosis.
The model then dynamically calculated the number of
patients diagnosed in each cycle, multiplying the number
of syncopes by the probability of obtaining a diagnosis
should syncope recur. Generally speaking, this approach
can increase the validity of the sensitivity analyses since
both critical variables (rate of syncope recurrence and
probability of successful ECG capturing) can be tested and
varied independently of each other. A cycle length of 3
months was used in the model, thus ensuring the possibil-
ity that a patient suffers more than one event per year.
Study population
Our study population was composed of patients with
unexplained and recurrent syncope leading to a Hospital
or Emergency Department admission, with an average
starting age of 61 years old, following the patient popula-
tion characteristics from the recent PICTURE study, the
largest international study using ILR regarding the type
and frequency of investigations that are usually per-
formed in the standard diagnostic pathway [21].
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whose etiology was not clarified after a clinical history,
physical examination and 12-lead ECG. In order to define
the number of patients to consider in the model we used
the latest National official Diagnosis-Related Groups (DRG)
Report published by the Central Administration of Health
System (ACSS) and assumed the number of syncope events
remained constant in recent years. According to this report
there were a total of 1010 hospital admissions, either in an
inpatient or ambulatory setting due to syncope (DRG 141
and 142) in the Portuguese National Health System Hospi-
tals in 2006 [22]. From 1010 hospital admissions due to
syncope, we assumed that 19.5% were due to unexplained
and recurrent syncope [21,23]. Consequently the analysis
considered a sample of 197 patients for each of the treat-
ment groups being compared.
Sources used were published investigations (approved
by the authors’ institutional Ethics Committees) and data
from National regulatory authorities. No human partici-
pants were directly included or recruited in this study.
Only a model/simulation was built according to the avail-
able data/evidence for this population.
Costs
In order to provide an estimation of the average cost of a
syncope episode admission, we have considered five scenar-
ios, using data on the frequency of a range of diagnostic
rests from the various studies recently published on syn-
cope management (Sousa Pedro [24] Edvardsson [21];
Baron-Esquiviais [7]; Brignole [4]; Farwell [16]) to which we
applied the unit costs/prices published by the Portuguese
National Health Service prices table [25]. Using a conserva-
tive approach, we decided to exclude from the analysis the
exams for which Portuguese unitary costs were not avail-
able. The average diagnostic cost per syncope was deter-
mined to be between 72.41€ and 1,112.02€ (see details
in Table 1); in the base-case analysis, a diagnostic cost
of 164.32€ was applied (based on Sousa Pedro [24]) to
all syncope events in the CDP arm (regardless of
whether a successful diagnosis was made), and to syn-
cope events occurring in the ILR arm beyond the 3-year
device battery life.
In addition to this cost, we estimated the cost of trauma/
injury in patients suffering recurrent syncope. Due to a lack
of Portuguese micro-costing data regarding trauma and in-
jury in syncope patients, we used two DRG tariffs as a
proxy for the cost of injury/trauma in an inpatient setting.
These DRGs were considered since, although not referring
to episodes where syncope is the main diagnosis, they refer
to episodes where syncope is coded as a secondary diagno-
sis and reflect the resource consumption regarding injury/
trauma in these patients. According to Sousa Pedro et al.
[24], 52.2% of syncope episodes are associated with trauma,
while Bartolleti et al. [26] reports that 16.16% of traumas/injuries are severe. Combining these figures with the se-
lected DRG tariffs for minor and major trauma (2,684.83€
and 6,058.25€, respectively – see Table 2), gives an average
cost of injury/trauma of 1,687.57€ per syncope event.
The costs associated with the ILR were accounted for in
four ways: device acquisition, implantation, follow-up and
explantation. The acquisition cost of the ILR was consid-
ered to be 2,000€ (based on the price of the Reveal® DX
loop recorder in Portugal), which is in line with the studies
reported by Davis et al., [27,28] to which a device implant-
ation cost of 127.80€ was added, based on the Portuguese
National Health Service official prices table (Code 41395)
[25]. Further, it was assumed that patients with an active
device would require two device check visits per year,
using the official tariff for a medical consultation of 31€
per visit [25]. Finally, the cost of device explantation was
applied at the time of diagnosis or after three years – this
cost was set equal to the cost of implantation. This last
cost was not applied to patients who died within the first
three years of the model.
All costs were discounted at 5% per year, in accord-
ance with the Portuguese Guidelines for Economic Drug
Evaluation Studies [29].
Scenarios presented
The primary outputs from this analysis were the number
of diagnosed patients and the cost of syncope admissions
and diagnosis in both groups (ILR and CDP). The model
was run over both lifetime and 3-year time horizons to il-
lustrate the cost profile over time. One-way sensitivity
analysis was undertaken to explore the impact of uncer-
tainty in specific model parameters and to use data from
alternative sources. Probabilistic sensitivity analysis was
also performed, incorporating uncertainty in the following
parameters: hazard ratio of death; number of syncope
events per year; probability and unit cost of each diagnos-
tic test; cost of device acquisition, implantation, follow-up
and explantation; probability and cost of major and minor
trauma; diagnostic yield of each diagnostic pathway. In the
probabilistic analysis, uncertainty was characterised by
specifying a probability distribution for each model par-
ameter. The probability distributions used were selected
to be appropriate for the type of parameter e.g. lognormal
distribution for the hazard ratio of death and the syncope
recurrence rate, gamma distributions for all cost parame-
ters and beta distributions for all probability-based param-
eters (probabilities of syncope diagnosis and of the use of
each diagnostic test). Monte-Carlo simulation was then
used to sample a value from each parameter’s distribution
and propagate the uncertainty through the model to gen-
erate a set of plausible outputs. Ten thousand simulations
were undertaken to ensure that the effect of the uncer-
tainty was fully captured. The probabilistic analysis was re-
peated for each of the five scenarios, using different study
Table 1 Average cost of diagnostic exams per patient with syncope
Investigations [21] Unit
prices






















Standard electrocardiogram 6.50€ 100% 6.50€ 98% 6.37€ 95,6% 6.21€ 100% 6.50€ - - Code 40301
Echocardiography 53.20€ 72.2% 38.41€ 86% 45.75€ 2,1% 1.12€ 16% 8.51€ 15.31% 8.14€ Code 40550
Overload echocardiography 85.30€ 1.60% 1.36€ - - - - - Code 40550;40315
Abdominal echography 20.12€ - - - - - - 2% 0.40€ - - Code 17130
Basic laboratory tests - - - - Pack Estimationa
With/enzymes tests 65.87€ 86% 56.65€ 35% 23.05€
Without enzymes tests 53.87€ 70,2% 37.82€
Enzymesb 34.40€ - - - - 30,2% 10.39€ - - - - Pack Estimationb
Ambulatory ECG monitoring 43.70€ - - 67% 29.28€ - - 11.22% 4.91€ Code 40405
ELR 47.30€ - - - - - - - - 28.57% 13.51€
In-Hospital ECG monitoring 124.70€ 61.20% 76.32€ 55% 68.59€ 17,1% 21.32€ 11% 13.72€ - - Code 40495 + daily
admission (85€)
Exercise testing 32.10€ 19.60% 6.29€ 52% 16.69€ - - 3% 0.96€ - - Code 40315
MRI or CT scan 97.45€ 1.60% 1.56€ 47% 45.80€ - - 15% 14.62€ - - Codes 18010; 16010
MRI 127.90€ - - - - - - - - 1.02% 1.31€ Code 18010
Brain CT scan 67.00€ - - - - 9% 6.03€ - - 8.16% 5.47€ Code 16010
Thorax CT scan 74.70€ - - - - 1,1% 0.82€ - - - - Code 16060
Chest X-ray 9.00€ - - - - 51,9% 4.67€ 12% 1.08€ - - Code 10406
Electroencephalography 58.80€ 1.20% 0.71€ 39% 22.93€ - - 6% 3.53€ 2.04% 1.20€ Code 63010
Carotid sinus massage 6.50€ 2.90% 0.19€ 36% 2.34€ 0,5% 0.03€ 15% 0.98€ - - Code 40301
Carotid echo-doppler 23.17€ 12.70% 2.94€ - - - - 4% 0.93€ 5.10% 1.18€ Code 17290
TILT test 124.10€ 15.90% 19.73€ 35% 43.44€ - - 13% 16.13€ - - Code 41120
Electrophysiology testing 2,488.72€ - - 25% 622.18€ - - 3% 74.66€ 1.02% 25.40€ Code 40950
Coronary angiography 531.44€ - - 23% 122.23€ - - 2% 10.63€ - - Code 40820
External loop recording 47.30€ 11.80% 5.58€ 12% 5.68€ - - - - - - Code 40479
Orthostatic blood pressure
movements
4.00€ - - 48% 1.92€ 4,6% 0.18€ - - - - Code 99230
Hypertension map 59.20€ 6.90% 4.08€ - - - - - - - - Code 41010
Neurological or
psychiatric evaluation
























- - 3% - - - - - - - Not considered
Others - - - 9% - 7,20% - 13% - - - Not considered
Total cost - - 164.32€ - 1,112.02€ 88.51€ - 173.31€ - 72.41€
aBasic Laboratory costs were estimated considering a standard pack of analysis: Creatinine, Hemogram with leukocyte formula, urea, capillary blood glucose determination, Ionogram (Na, K, Cl), Proteins (total), Albumin
Ultra-sensitive C-reactive protein, Summary analysis of Urine, acid-base balance (pH, pCO2, pO2, SatO2, CO2), D- Dimer (DD); and prothrombin time (TP, Quick, INR), (with or without: Troponin T or I, alanine aminotransferase
(ALT), aspartate aminotransferase (AST)).
bEnzymes tests: Troponin T or I, Creatine kinase (CK), Myoglobin (Mb), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactic dehydrogenase (LDH).



















Table 2 Injury/trauma diagnosis-related groups [25]
DRG Description Tariff [25] Occurrence of minor/major
trauma [24] [26]
Injury/trauma due to syncope
average cost estimation
767 Stupor and/or traumatic coma, coma <1
hour age > 17 years without CC
2,684.83 € 52.2% *(1-16.16%) = 43.8% 1,687.57 €
468 Extensive procedures in the Operating Room,
unrelated to principal diagnosis
6,058.25 € 52.2% *16.16% = 8.45%
Legend: DRG – Diagnosis-Related-Group; CC- Complications/comorbidities.
“*” means “multiply”. E.g. 52.2% multiplied by (100-16.16%).
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CDP arm. A summary table of the parameters of each
probability distribution is provided in the Additional file 1.
Results
Deterministic analysis
After running the model for both three-year and lifetime
horizons it was possible to estimate the financial impact
for the two patient groups (see Table 3). From 197 Patients
in the ILR group, 135 (68.5%) were diagnosed within a 3-
year period and of these, 64 (47.4%) were diagnosed in the
first year. By contrast, 40 (20.3%) of the patients from the
CDP group were diagnosed in the first three years. The
total cost of hospital admissions in a three-year time hori-
zon due to syncope was 23% lower in the ILR group than
in the CDP Group in the base-case analysis, after factoring
in the costs of diagnostic tests in the CDP group
(1,204,621€ for the ILR group, versus 1,571,332€ for the
CDP group - this translates to a saving of 1,861€ per pa-
tient). In all four of the other main scenarios tested (using
diagnostic test frequency data from other studies), ILR led
to an earlier diagnosis and consequently to a lower num-
ber of syncope hospital admissions, allowing important
hospital cost offsets, with savings of between 307,872€ andTable 3 Number of syncope hospital admissions, diagnosed pat
Model output ILR
Time horizon Lifetime 3 year
Number of patients diagnosed 175 135
Number of patients undiagnosed and alive 1 58
Total syncope episodes 531 215
Number of injuries (major and minor) 278 112
Costs – device acquisition 394,000€ 394,000
Costs – device-related expenses 71,101€ 71,101
Costs – syncope admissions 705,292€ 353,756
Costs – diagnostic tests* 34,228€ 0€
Costs – total (Sousa Pedro) 1,204,621€ 818,857
Costs – total (Edvardsson) 1,402,037€ 818,857
Costs – total (Baron-Esquivias) 1,188,830€ 818,857
Costs – total (Brignole) 1,206,495€ 818,857
Costs – total (Farwell) 1,185,476€ 818,857
*Diagnostic test costs calculated from resource use data reported by Sousa Pedro [
instead use the diagnostic test resource use data from the respective studies.973,429€ for the entire cohort (1,563€–4,941€ per patient)
over a lifetime horizon (Table 3). Over a 3-year horizon,
costs were higher in the ILR group, due to the up-front
cost of device acquisition and implantation.
One-way sensitivity analysis
The results of the one-way sensitivity analysis are shown
in Figure 2. The x-axis represents the per-patient cost sav-
ings in the ILR arm over a lifetime horizon. The vertical
line in the centre of the chart represents the deterministic
cost savings for the ILR group, the bars towards the top of
the chart show the parameters whose uncertainty has the
most influence upon this outcome (the numbers at either
end of each bar represent the range of values used for each
input parameter), and the values in brackets show the
base-case value of each input parameter. The ranges used
for each parameter were specified either by using data
from other studies or by halving (or doubling) the base-
case values (for example, the upper bound of 0.78 used for
the diagnosis probability in the ILR arm was based on
PICTURE; the upper bound of 0.81 for the number of syn-
copes per year was reported by an earlier publication of
the EaSyAS study (Farwell, (16)). Based on this analysis,
the key parameters appear to be: the diagnosis probabilityients and costs for ILR and CDP groups in different scenarios
CDP Overall savings
s Lifetime 3 years Lifetime 3 years
143 40 32 95
2 152 -1 -94
1,141 315 610 100
596 165 318 53
€ 0€ 0€ -394,000€ -394,000€
€ 0€ 0€ -71,101€ -71,101€
€ 1,431,910€ 513,879€ 726,618€ 160,123€
139,422€ 50,035€ 105,194€ 50,035€
€ 1,571,332€ 563,915€ 366,711€ -254,943€
€ 2,375,465€ 852,499€ 973,429€ 33,642€
€ 1,507,011€ 540,831€ 318,181€ -278,026€
€ 1,578,965€ 566,654€ 372,470€ -252,203€
€ 1,493,347€ 535,928€ 307,872€ -282,929€
24]. The ‘total’ results for Edvardsson, Baron-Esquivias, Brignole and Farwell
Figure 2 Tornado diagram (one-way sensitivity analysis). Numbers in brackets represent the deterministic value of each parameter; the
numbers at each end of the bars represent the lower and upper bounds of the value used for each parameter.
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the probability of injury per syncope event; and the syn-
cope rate per year. ILR is projected to provide cost savings
in all but two scenarios; the first of these involved redu-
cing the probability of injury to 0.25 (from 0.522 in the
base-case), while the second involved setting the probabil-
ity of diagnosis in the ILR arm to be equal to that in the
CDP arm, representing an extremely conservative ap-
proach. To explore this latter scenario more thoroughly,
we examined the relationship between the probability of
diagnosis with ILR and the overall cost savings predicted
by the model. This relationship is shown in Figure 3 and
indicates that with our model, provided that the probabil-
ity of diagnosis with ILR is above 35% and the absolute in-
cremental probability of diagnosis versus CDP is at least
17.5%, ILR is projected to provide cost savings compared
with CDP. None of the diagnostic test costs had a signifi-
cant impact upon the cost savings calculated from the
model.Figure 3 One-way sensitivity analysis – relationship between ILR diagProbabilistic sensitivity analysis
The probabilistic analysis was performed initially using the
resource use assumptions from Sousa et al. [24]. Based on
the set of 10,000 sampled input parameter values, the mean
lifetime savings for the ILR group compared with the CDP
group were 411,167€ for the entire cohort (or 2,087€ per
patient). Figure 4 shows a histogram of the cost savings
(ILR versus CDP) for the 10,000 probabilistic runs – it can
be observed that the significant majority (91.1%) of these
resulted in cost savings in the ILR group. Probabilistic ana-
lyses were also performed under the four other scenarios
(using resource data from different studies). In each case, at
least 87% of simulations resulted in cost savings in the ILR
group over a lifetime horizon.
Discussion
We used a Markov Model based on government data and
landmark international papers to compare the cost of ILR
use versus CDP in unexplained recurrent syncope patients.nosis probability and lifetime cost savings.
Figure 4 Probabilistic analysis results - lifetime savings for ILR.
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hospital admissions and investigations, suggesting its poten-
tial for significant cost offsets in the Portuguese National
Health Service.
We have considered five scenarios based on data from
different studies recently published in this subject area. We
consider PICTURE [21] to be the most appropriate sce-
nario since the study population enrolled most closely re-
sembles ILR-indicated patients and thus the diagnostic tests
observed are the ones with a higher likelihood of resem-
bling the tests performed on unexplained syncope patients.
The remaining scenarios used data from studies that fo-
cused generally on syncope patients and therefore included
patients not indicated for ILR. Nevertheless, we believe
there is value in testing all possible scenarios. Although
PICTURE seems to better reflect the study population, we
have used Sousa Pedro study as our base-case scenario,
since it reports data from a Portuguese Population.
Under every scenario considered, ILR appears to be sig-
nificantly cost-saving over a lifetime horizon. One-way
sensitivity analyses failed to identify any plausible scenario
under which ILR use does not result in significant cost-
savings, prompting us to believe that ILRs should be of-
fered to indicated patients. Probabilistic sensitivity analysis
suggested that ILR is very likely to be cost-saving over a
lifetime horizon, based on the modelling approach used
and specification of parameter uncertainty.
The diagnosis rates predicted by the model closely
match the data reported by Farwell et al. [16] and are
aligned with the observations of Krahn et al. [12] Longer-
term projections of the proportion of patients diagnosed
also support long-term follow-up of the ISSUE-2 study, in
which it has been projected that 80% of patients with an
ILR would be diagnosed within four years [30].The discrepancy between the guideline indications for
the implantation of ILRs and their use in clinical practice
has been described by Vitale E et al. [31] for the Italian
population. Nevertheless, we highlight than in the 2005 to
2007 period, ILR implants in Italy were approximately
three times more frequent (10 to 20 per million inhabi-
tants) than in Portugal, where a very low number of im-
plants has been observed: six ILRs per million inhabitants
were implanted in 2011 [32]. This was about four to five
times less than in Western Europe (15 to 28 ILRs per mil-
lion inhabitants) and eight to ten times less than in the
United Kingdom (28 to 59 ILRs per million inhabitants)
[33], and well below the EHRA recommended rate of 135
implants/million [17].
If a total of 197 patients with unexplained syncope,
as considered in this analysis, were implanted with ILR
per year this would lead to an implant rate of 20 ILRs
per million inhabitants, which would be in line with
the practice from other European countries and would
lead to considerable cost offsets to the Portuguese
National Health Service. According to these results,
limiting the use of ILRs in patients with a clear clinical
indication leads to an increase in the number of other
investigations and avoidable injuries. This in turn re-
sults in an increase of expenditure compared with other
European countries. Furthermore, in the Portuguese
context the use of ILR seems to occur in a late stage of
the diagnostic workup of syncope. This suggests that
patients have probably already undergone an exhaustive
assessment with many investigations; this could mean
that these patients have already used a lot of valuable
healthcare resources which could have been invested
elsewhere if ILR had been used earlier in the diagnostic
pathway.
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period have also demonstrated a favourable cost-benefit
ratio. In the Randomized Assessment of Syncope Trial
(RAST) ILR usage was compared with a conventional
strategy (including the use of external loop recorder
during 2 to 4 weeks, TILT testing and electrophysio-
logical study - EPS) and achieved a higher frequency
of diagnosis in subjects with unexplained syncope
(55% versus 19%; p = 0.0014) [12]. The same study
demonstrated the superior cost-effectiveness perform-
ance of the ILR strategy translated by a reduced cost-
per-successful-diagnosis using ILRs; 5,852$ CAD for
each diagnosis versus 8,414$ CAD in the conventional
strategy group [15].
In the Eastbourne Syncope Assessment Study (EaSyAS) a
further evaluation of the impact of the ILR compared to
conventional investigation was performed. The invasive
strategy achieved earlier, more diverse and more fre-
quent (hazard ratio 8.93 95% CI 3.17–25.2, p < 0.0001)
diagnosis, resulting in cost savings (mean difference of
£809) [19]. Additionally, the diagnostic accuracy, safety,
reliability and usefulness of the ILR has already been
demonstrated in recent trials and in specific popula-
tions, such as patients with congenital heart disease
[21,34,35] and patients undergoing magnetic resonance
imaging [36].
Study limitations
Incidence of DRG codes to estimate the size of the
population may be associated with some error. Under-
estimation may occur in patients admitted with trauma
due to syncope, if the type of lesion is codified as the
main diagnosis and syncope is not introduced/codified.
Conversely, if patients were admitted twice in the same
year, that may have led to some degree of overesti-
mation of the total number of patients. However, we
think that these events may correspond to a minority of
cases and may have partially and mutually neutralized
themselves, since one led to overestimation and the
other to underestimation.
We do not know for sure the Portuguese reality re-
garding the number and type of investigations that are
performed before obtaining a diagnosis of referral of
the patient to an ILR, namely the number of 24-hour
Holter monitoring tests, external loop recorders, trans-
thoracic echocardiogram, blood tests, head Computed
Tomography scans and coronary angiograms exams.
Sousa and colleagues report data from a syncope unit
in the south of Portugal, and although it refers specific-
ally to Portuguese practice in syncope management, it is
a very unique case in the country and therefore may not
reflect the national reality [24]. Nevertheless, taking into
account the very low incidence of ILR implants in our
country, a possible deviation is for having a higher numberand more diverse type of investigations in Portugal, which
would actually underestimate the expenditure with investi-
gations, leading to a more favourable cost profile for ILR.
For the diagnostic yield, we used assumptions based
on the EaSyAS study [19] for both treatment groups.
EaSyAS was conducted with an earlier ILR device ver-
sion, while the more recent PICTURE study was con-
ducted with ILRs which have vastly improved auto-
detection algorithms [13,21. Since the devices currently
on the market are DX/XT we consider the base-case re-
sults described here to be represent conservative esti-
mates of the savings possible through wider use of ILRs.
Furthermore, our study considered only the initial
costs of injuries sustained as a result of syncope epi-
sodes (using the tariffs for minor and major injuries).
This is likely to under-estimate the total costs of injury
management, since it does not account for the on-
going costs of managing serious injuries and long-
term sequelae [37]. Bartoletti reports that the majority
of syncope-related traumas are to the head, suggesting
that managing these events would in many cases in-
volve greater costs than that of the initial hospitalisa-
tion [26].
Conclusions
These results demonstrate that the use of an implantable
loop recorder early in the assessment of patients with re-
current unexplained syncope has a favourable cost profile
in the Portuguese context.
Based on the very low utilization of these devices in
Portugal when compared with most European countries,
we can assume that a stricter compliance with the 2009
ESC syncope guidelines may lead to an earlier use and im-
portant reduction in health care expenditure associated
with unexplained recurrent syncope patients.
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